The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.
Source: BioPharma Dive
You may also like
This common pesticide may be quietly wiping out future...
Boehringer Ingelheim’s Jascayd approved by MHRA for...
Ipsen to acquire Memo Therapeutics in deal worth more...
Macrophage Membrane-Derived Nanoparticles Shows...
Epigenomic Analysis Uncovers New AML Subgroups and...
Bausch + Lomb gives up on glaucoma eye drop hopeful...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.